nach oben

Journal of Neurology

Erschienen in:

10.05.2023 | Original Communication

Neurological and imaging phenotypes of adults with untreated phenylketonuria: new cases and literature review

verfasst von: Meng-Wen Wang, Chu-Jun Wu, Zai-Qiang Zhang

Erschienen in: Journal of Neurology | Ausgabe 8/2023

Einloggen, um Zugang zu erhalten

Abstract

Objectives

Phenylketonuria (PKU) is the most prevalent congenital disease of amino acid metabolism. Neurological manifestations usually complicate PKU in untreated adult patients. This study describes neurological and imaging phenotypes of adult patients with untreated PKU.

Methods

We investigated a cohort of 320 unrelated adult patients with suspected genetic leukoencephalopathies using whole-exome sequencing (WES). We analyzed the phenotypic features of adult PKU patients in our cohort and summarized cases reported in the literature.

Results

We identified 10 patients in our cohort and 12 patients in the literature, who presented with neurological manifestations and were diagnosed with PKU in adulthood. Approximately 60% of these patients had onset of clinical features in adulthood. The most common neurological symptoms of patients presenting in adulthood were cognitive disturbance and spastic paralysis, followed by vision loss, cerebellar ataxia, weakness of limbs, and seizure. This differed from that of patients presenting with PKU features in childhood, who consistently had mental retardation with various neurological complications emerging during a broad age range. Imaging findings were similar between patients presenting with clinical features in childhood compared with adulthood, comprising symmetric periventricular white matter hyperintense on T2-weighted imaging and diffusion-weighted imaging predominantly in the parietal and occipital lobes. Also, normal brain imaging and diffuse leukoencephalopathies were observed in both patient groups.

Conclusion

PKU with clinical features presenting in adulthood is an atypical subtype and should be considered during diagnosis of adults with neurological symptoms and leukoencephalopathy. DWI seems to be most helpful to distinguish patients with PKU. Additionally, we demonstrate that PKU constitutes a part (3.1%) of adult genetic leukoencephalopathies.

Hillert A, Anikster Y, Belanger-Quintana A et al (2020) The genetic landscape and epidemiology of phenylketonuria. Am J Hum Genet 107(2):234–250. https://doi.org/10.1016/j.ajhg.2020.06.006CrossRefPubMedPubMedCentral

van Spronsen FJ, Blau N, Harding C, Burlina A, Longo N, Bosch AM (2021) Phenylketonuria. Nat Rev Dis Primers 7(1):36. https://doi.org/10.1038/s41572-021-00267-0CrossRefPubMedPubMedCentral

Weglage J, Oberwittler C, Marquardt T, Schellscheidt J, von Teeffelen-Heithoff A, Koch G, Gerding H (2000) Neurological deterioration in adult phenylketonuria. J Inherit Metab Dis 23(1):83–4. https://doi.org/10.1023/a:1005607115309CrossRefPubMed

Kasim S, Moo LR, Zschocke J, Jinnah HA (2001) Phenylketonuria presenting in adulthood as progressive spastic paraparesis with dementia. J Neurol Neurosurg Psychiatry 71(6):795–797. https://doi.org/10.1136/jnnp.71.6.795CrossRefPubMedPubMedCentral

Jousserand G, Antoine JC, Camdessanché JP (2010) Musty odour, mental retardation, and spastic paraplegia revealing phenylketonuria in adulthood. J Neurol 257(2):302–304. https://doi.org/10.1007/s00415-009-5358-1CrossRefPubMed

Rosini F, Rufa A, Monti L, Tirelli L, Federico A (2014) Adult-onset phenylketonuria revealed by acute reversible dementia, prosopagnosia and parkinsonism. J Neurol 261(12):2446–2448. https://doi.org/10.1007/s00415-014-7492-7CrossRefPubMed

Holtzman C, Slazyk WE, Cordero JF, Hannon WH (1986) Descriptive epidemiology of missed cases of phenylketonuria and congenital hypothyroidism. Pediatrics 78(4):553–558 CrossRefPubMed

van Wegberg AMJ, Trefz F, Gizewska M, Study Group on Missed PKU and Missed to Follow-Up et al (2021) Undiagnosed phenylketonuria can exist everywhere: results from an international survey. J Pediatr 239:231-234e2. https://doi.org/10.1016/j.jpeds.2021.08.070CrossRefPubMed

van Vliet D, van Wegberg AMJ, Ahring K et al (2019) Untreated PKU patients without intellectual disability: what do they teach us? Nutrients 11(11):2572. https://doi.org/10.3390/nu11112572CrossRefPubMedPubMedCentral

10.

Anderson PJ, Leuzzi V (2010) White matter pathology in phenylketonuria. Mol Genet Metab 99(Suppl 1):S3-9. https://doi.org/10.1016/j.ymgme.2009.10.005CrossRefPubMed

11.

Koch R, Moseley K, Ning J, Romstad A, Guldberg P, Guttler F (1999) Long-term beneficial effects of the phenylalanine-restricted diet in late-diagnosed individuals with phenylketonuria. Mol Genet Metab 67(2):148–155. https://doi.org/10.1006/mgme.1999.2863CrossRefPubMed

12.

Coker SB (1991) The diagnosis of childhood neurodegenerative disorders presenting as dementia in adults. Neurology 41(6):794–798. https://doi.org/10.1212/wnl.41.6.794CrossRefPubMed

13.

Gray RGF, Preece MA, Green SH et al (2000) Inborn errors of metabolism as a cause of neurological disease in adults: approach to investigation. J Neurol Neurosurg Psychiatry 69:5–12. https://doi.org/10.1136/jnnp.69.1.5CrossRefPubMedPubMedCentral

14.

Mak CM, Lee HC, Chan AY, Lam CW (2013) Inborn errors of metabolism and expanded newborn screening: review and update. Crit Rev Clin Lab Sci 50(6):142–162. https://doi.org/10.3109/10408363.2013.847896CrossRefPubMed

15.

Wang C, Li J (2018) Subacute onset leukodystrophy and visual-spatial disorders revealing phenylketonuria combined with homocysteinmia in adulthood: a case report. Medicine 97(8):e9801. https://doi.org/10.1097/MD.0000000000009801CrossRefPubMedPubMedCentral

16.

Liu Y, Dong Z, Yu S (2018) Late-diagnosed phenylketonuria mimicking x-linked adrenoleukodystrophy with heterozygous mutations of the PAH Gene: a case report and literature review. Clin Neurol Neurosurg 171:151–155. https://doi.org/10.1016/j.clineuro.2018.06.009CrossRefPubMed

17.

Lynch DS, Wade C, Paiva ARB et al (2019) Practical approach to the diagnosis of adult-onset leukodystrophies: an updated guide in the genomic era. J Neurol Neurosurg Psychiatry 90(5):543–554. https://doi.org/10.1136/jnnp-2018-319481CrossRefPubMed

18.

Li H (2014) Toward better understanding of artifacts in variant calling from high-coverage samples. Bioinformatics 30(20):2843–2851. https://doi.org/10.1093/bioinformatics/btu356CrossRefPubMedPubMedCentral

19.

McKenna A, Hanna M, Banks E et al (2010) The genome analysis toolkit: a mapreduce framework for analyzing next-generation DNA sequencing data. Genome Res 20(9):1297–1303. https://doi.org/10.1101/gr.107524.110CrossRefPubMedPubMedCentral

20.

Wang K, Li M, Hakonarson H (2010) ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data. Nucleic Acids Res 38(16):e164. https://doi.org/10.1093/nar/gkq603CrossRefPubMedPubMedCentral

21.

Plagnol V, Curtis J, Epstein M et al (2012) A robust model for read count data in exome sequencing experiments and implications for copy number variant calling. Bioinformatics 28(21):2747–2754. https://doi.org/10.1093/bioinformatics/bts526CrossRefPubMedPubMedCentral

22.

Richards S, Aziz N, Bale S et al (2015) Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med 17(5):405–424. https://doi.org/10.1038/gim.2015.30CrossRefPubMedPubMedCentral

23.

Ishimaru K, Tamasawa N, Baba M, Matsunaga M, Takebe K (1993) Phenylketonuria with adult-onset neurological manifestation. Rinsho Shinkeigaku 33(9):961–5 (Abstract)PubMed

24.

Daelman L, Sedel F, Tourbah A (2014) Progressive neuropsychiatric manifestations of phenylketonuria in adulthood. Rev Neurol (Paris) 170(4):280–287. https://doi.org/10.1016/j.neurol.2013.09.012CrossRefPubMed

25.

Narayanan D, Barski R, Henderson MJ et al (2014) Delayed diagnosis of phenylketonuria—a case report of two siblings. Ann Clin Biochem 51(Pt 3):406–408. https://doi.org/10.1177/0004563213503818CrossRefPubMed

26.

Chen S, Zhu M, Hao Y, Feng J, Zhang Y (2019) Effect of delayed diagnosis of phenylketonuria with imaging findings of bilateral diffuse symmetric white matter lesions: a case report and literature review. Front Neurol 4(10):1040. https://doi.org/10.3389/fneur.2019.01040CrossRef

27.

Tufekcioglu Z, Cakar A, Bilgic B, Hanagasi H, Gurvit H, Emre M (2016) Adult-onset phenylketonuria with rapidly progressive dementia and Parkinsonism. Neurocase 22(3):273–275. https://doi.org/10.1080/13554794.2016.1142567CrossRefPubMed

28.

Guida M, Pesaresi I, Fabbri S, Sartucci F, Cosottini M, Giorgi FS (2014) Epilepsy and phenylketonuria: a case description and EEG-fMRI findings. Funct Neurol 29(1):75–9PubMedPubMedCentral

29.

Jaulent P, Charriere S, Feillet F, Douillard C, Fouilhoux A, Thobois S (2020) Neurological manifestations in adults with phenylketonuria: new cases and review of the literature. J Neurol 267(2):531–542. https://doi.org/10.1007/s00415-019-09608-2CrossRefPubMed

30.

Younger DS (1993) Differential diagnosis of progressive spastic paraparesis. Semin Neurol 13(4):319–321. https://doi.org/10.1055/s-2008-1041141CrossRefPubMed

31.

Zhovtis Ryerson L, Herbert J, Howard J, Kister I (2014) Adult-onset spastic paraparesis: an approach to diagnostic work-up. J Neurol Sci 346(1–2):43–50. https://doi.org/10.1016/j.jns.2014.09.015CrossRefPubMed

32.

Cleary MA, Walter JH, Wraith JE, Jenkins JP, Alani SM, Tyler K, Whittle D (1994) Magnetic resonance imaging of the brain in phenylketonuria. Lancet 344(8915):87–90. https://doi.org/10.1016/s0140-6736(94)91281-5CrossRefPubMed

33.

Manara R, Burlina AP, Citton V, Ermani M, Vespignani F, Carollo C, Burlina AB (2009) Brain MRI diffusion-weighted imaging in patients with classical phenylketonuria. Neuroradiology 51(12):803–812. https://doi.org/10.1007/s00234-009-0574-zCrossRefPubMed

34.

Scarabino T, Popolizio T, Tosetti M et al (2009) Phenylketonuria: white-matter changes assessed by 3.0-T magnetic resonance (MR) imaging, MR spectroscopy and MR diffusion. Radiol Med 114(3):461–74. https://doi.org/10.1007/s11547-009-0365-yCrossRefPubMed

35.

Hawks Z, Hood AM, Lerman-Sinkoff DB et al (2019) White and gray matter brain development in children and young adults with phenylketonuria. Neuroimage Clin 23:101916. https://doi.org/10.1016/j.nicl.2019.101916CrossRefPubMedPubMedCentral

36.

Pearsen KD, Gean-Marton AD, Levy HL, Davis KR (1990) Phenylketonuria: MR imaging of the brain with clinical correlation. Radiology 177(2):437–440. https://doi.org/10.1148/radiology.177.2.2217781CrossRefPubMed

37.

Leuzzi V, Tosetti M, Montanaro D et al (2007) The pathogenesis of the white matter abnormalities in phenylketonuria. A multimodal 3.0 tesla MRI and magnetic resonance spectroscopy (1H MRS) study. J Inherit Metab Dis 30(2):209–16. https://doi.org/10.1007/s10545-006-0399-4CrossRefPubMed

38.

van Vliet D, van Wegberg AMJ, Ahring K et al (2018) Can untreated PKU patients escape from intellectual disability? A systematic review. Orphanet J Rare Dis 13(1):149. https://doi.org/10.1186/s13023-018-0890-7CrossRefPubMedPubMedCentral

39.

Bouchlariotou S, Tsikouras P, Maroulis G (2009) Undiagnosed maternal phenylketonuria: own clinical experience and literature review. J Matern Fetal Neonatal Med 22(10):943–948. https://doi.org/10.1080/14767050902994697CrossRefPubMed

40.

Hanley WB (2008) Finding the fertile woman with phenylketonuria. Eur J Obstet Gynecol Reprod Biol 137(2):131–135. https://doi.org/10.1016/j.ejogrb.2007.12.011CrossRefPubMed

41.

Moats RA, Koch R, Moseley K, Guldberg P, Guttler F, Boles RG, Nelson MD Jr (2000) Brain phenylalanine concentration in the management of adults with phenylketonuria. J Inherit Metab Dis 23(1):7–14. https://doi.org/10.1023/a:1005638627604CrossRefPubMed

42.

Möller HE, Weglage J, Wiedermann D, Ullrich K (1998) Blood-brain barrier phenylalanine transport and individual vulnerability in phenylketonuria. J Cereb Blood Flow Metab 18(11):1184–1191. https://doi.org/10.1097/00004647-199811000-00004CrossRefPubMed

43.

Leuzzi V, Bianchi MC, Tosetti M, Carducci CL, Carducci CA, Antonozzi I (2000) Clinical significance of brain phenylalanine concentration assessed by in vivo proton magnetic resonance spectroscopy in phenylketonuria. J Inherit Metab Dis 23(6):563–570. https://doi.org/10.1023/a:1005621727560CrossRefPubMed

44.

van Spronsen FJ, Hoeksma M, Reijngoud DJ (2009) Brain dysfunction in phenylketonuria: is phenylalanine toxicity the only possible cause? J Inherit Metab Dis 32(1):46–51. https://doi.org/10.1007/s10545-008-0946-2CrossRefPubMed

45.

Ferreira BK, Rodrigues MT, Streck EL, Ferreira GC, Schuck PF (2021) White matter disturbances in phenylketonuria: possible underlying mechanisms. J Neurosci Res 99(1):349–360. https://doi.org/10.1002/jnr.24598CrossRefPubMed

46.

Reynolds R, Burri R, Herschkowitz N (1993) Retarded development of neurons and oligodendroglia in rat forebrain produced by hyperphenylalaninemia results in permanent deficits in myelin despite long recovery periods. Exp Neurol 124(2):357–367. https://doi.org/10.1006/exnr.1993.1206CrossRefPubMed

47.

Dyer CA, Kendler A, Philibotte T, Gardiner P, Cruz J, Levy HL (1996) Evidence for central nervous system glial cell plasticity in phenylketonuria. J Neuropathol Exp Neurol 55(7):795–814. https://doi.org/10.1097/00005072-199607000-00005CrossRefPubMed

48.

Koch R, Verma S, Gilles FH (2008) Neuropathology of a 4-month-old infant born to a woman with phenylketonuria. Dev Med Child Neurol 50(3):230–233. https://doi.org/10.1111/j.1469-8749.2008.02028.xCrossRefPubMed

49.

Schoemans R, Aigrot MS, Wu C et al (2010) Oligodendrocyte development and myelinogenesis are not impaired by high concentrations of phenylalanine or its metabolites. J Inherit Metab Dis 33(2):113–120. https://doi.org/10.1007/s10545-010-9052-3CrossRefPubMedPubMedCentral

50.

van der Knaap MS, Bugiani M (2017) Leukodystrophies: a proposed classification system based on pathological changes and pathogenetic mechanisms. Acta Neuropathol 134(3):351–382. https://doi.org/10.1007/s00401-017-1739-1CrossRefPubMedPubMedCentral

51.

Malamud N (1966) Neuropathology of phenylketonuria. J Neuropathol Exp Neurol 25(2):254–268. https://doi.org/10.1097/00005072-196604000-00006CrossRefPubMed

52.

Huttenlocher PR (2000) The neuropathology of phenylketonuria: human and animal studies. Eur J Pediatr 159(Suppl 2):S102–S106. https://doi.org/10.1007/pl00014371CrossRefPubMed

53.

Vermathen P, Robert-Tissot L, Pietz J, Lutz T, Boesch C, Kreis R (2007) Characterization of white matter alterations in phenylketonuria by magnetic resonance relaxometry and diffusion tensor imaging. Magn Reson Med 58(6):1145–1156. https://doi.org/10.1002/mrm.21422CrossRefPubMed

54.

Sirrs SM, Laule C, Mädler B, Brief EE, Tahir SA, Bishop C, MacKay AL (2007) Normal-appearing white matter in patients with phenylketonuria: water content, myelin water fraction, and metabolite concentrations. Radiology 242(1):236–243. https://doi.org/10.1148/radiol.2421051758CrossRefPubMed

55.

Schiffmann R, van der Knaap MS (2009) Invited article: an MRI-based approach to the diagnosis of white matter disorders. Neurology 72:750–759. https://doi.org/10.1212/01.wnl.0000343049.00540.c8CrossRefPubMedPubMedCentral

56.

Wolf NI, Ffrench-Constant C, van der Knaap MS (2021) Hypomyelinating leukodystrophies - unravelling myelin biology. Nat Rev Neurol 17(2):88–103. https://doi.org/10.1038/s41582-020-00432-1CrossRefPubMed

57.

van Wegberg AMJ, MacDonald A, Ahring K et al (2017) The complete European guidelines on phenylketonuria: diagnosis and treatment. Orphanet J Rare Dis 12(1):162. https://doi.org/10.1186/s13023-017-0685-2CrossRefPubMedPubMedCentral

58.

van Spronsen FJ, van Wegberg AM, Ahring K et al (2017) Key European guidelines for the diagnosis and management of patients with phenylketonuria. Lancet Diabetes Endocrinol 5(9):743–756. https://doi.org/10.1016/S2213-8587(16)30320-5CrossRefPubMed

59.

González MJ, Gutiérrez AP, Gassió R, Fusté ME, Vilaseca MA, Campistol J (2011) Neurological complications and behavioral problems in patients with phenylketonuria in a follow-up unit. Mol Genet Metab 104(Suppl):S73–S79. https://doi.org/10.1016/j.ymgme.2011.07.015CrossRefPubMed

60.

Xiang L, Tao J, Deng K et al (2019) Phenylketonuria incidence in China between 2013 and 2017 based on data from the Chinese newborn screening information system: a descriptive study. BMJ Open 9(8):e031474. https://doi.org/10.1136/bmjopen-2019-031474CrossRefPubMedPubMedCentral

61.

Mei L, Song P, Xu L (2013) Newborn screening and related policy against Phenylketonuria in China. Intractable Rare Dis Res 2(3):72–76. https://doi.org/10.5582/irdr.2013.v2.3.72CrossRefPubMedPubMedCentral

62.

Zhan JY, Qin YF, Zhao ZY (2009) Neonatal screening for congenital hypothyroidism and phenylketonuria in China. World J Pediatr 5(2):136–139. https://doi.org/10.1007/s12519-009-0027-0CrossRefPubMed

Titel: Neurological and imaging phenotypes of adults with untreated phenylketonuria: new cases and literature review
verfasst von: Meng-Wen Wang
Chu-Jun Wu
Zai-Qiang Zhang
Publikationsdatum: 10.05.2023
Verlag: Springer Berlin Heidelberg
Erschienen in: Journal of Neurology / Ausgabe 8/2023
Print ISSN: 0340-5354
Elektronische ISSN: 1432-1459
DOI: https://doi.org/10.1007/s00415-023-11760-9

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Neurologie

Nicht Creutzfeldt Jakob, sondern Abführtee-Vergiftung

29.05.2024 Hyponatriämie Nachrichten

Eine ältere Frau trinkt regelmäßig Sennesblättertee gegen ihre Verstopfung. Der scheint plötzlich gut zu wirken. Auf Durchfall und Erbrechen folgt allerdings eine Hyponatriämie. Nach deren Korrektur kommt es plötzlich zu progredienten Kognitions- und Verhaltensstörungen.

Schutz der Synapsen bei Alzheimer

29.05.2024 Morbus Alzheimer Nachrichten

Mit einem Neurotrophin-Rezeptor-Modulator lässt sich möglicherweise eine bestehende Alzheimerdemenz etwas abschwächen: Erste Phase-2-Daten deuten auf einen verbesserten Synapsenschutz.

Sozialer Aufstieg verringert Demenzgefahr

24.05.2024 Demenz Nachrichten

Ein hohes soziales Niveau ist mit die beste Versicherung gegen eine Demenz. Noch geringer ist das Demenzrisiko für Menschen, die sozial aufsteigen: Sie gewinnen fast zwei demenzfreie Lebensjahre. Umgekehrt steigt die Demenzgefahr beim sozialen Abstieg.

Hirnblutung unter DOAK und VKA ähnlich bedrohlich

17.05.2024 Direkte orale Antikoagulanzien Nachrichten

Kommt es zu einer nichttraumatischen Hirnblutung, spielt es keine große Rolle, ob die Betroffenen zuvor direkt wirksame orale Antikoagulanzien oder Marcumar bekommen haben: Die Prognose ist ähnlich schlecht.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Abstract

Objectives

Methods

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 8/2023

Acetyl-DL-leucine in combination with memantine improves acquired pendular nystagmus caused by multiple sclerosis: a case report

Autonomic nervous system disorders in multiple sclerosis

Self-reported life-space mobility in the first year after ischemic stroke: longitudinal findings from the MOBITEC-Stroke project

Understanding social media: how its popularity could be used to advance medical education in stroke care?

Path from discovery to recovery: therapeutic and diagnostic advances in Alzheimer's dementia